Frank Wainright

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

Retrieved on: 
Thursday, August 18, 2022

The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.

Key Points: 
  • The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.
  • The Company has applied to list the Conversion Shares, the Warrant Shares, the Debt Shares, and the Compensation Shares on the Canadian Securities Exchange (the "CSE").
  • The New Warrants will be subject to a four-month and one day hold period under applicable securities laws in Canada.
  • Prior to closing of the first Tranche, the Subscriber did not beneficially own or control any securities of the Company.

Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

Retrieved on: 
Wednesday, January 6, 2021

CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference.

Key Points: 
  • CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference.
  • Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021.
  • Jack Kenny will also be participating in a panel discussion hosted by former FDA Commissioner Scott Gottlieb, M.D.
  • For additional information on the H. C. Wainright Bioconnect 2021 Virtual Conference, please visit www.h c w events.com/bioconnect .